Share price · BIIB
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
See what was announced around each unusual move
Research flags the days this stock moved far more than its sector fund, lists the news, filings and earnings dated around each one, and shows how much of its unusual movement fell on each asset's announcements.
Assets
(17 total)
| Target & Modality | |||
|---|---|---|---|
| Approved | Nrf2 pathway (fumaric acid ester)Small molecule | Multiple Sclerosis | |
Diroximel fumarate(Vumerity) | Approved | Nrf2 pathway (fumaric acid ester)Small molecule | Multiple Sclerosis |
| Approved | Nrf2 pathway (fumaric acid ester)Small molecule | Multiple Sclerosis | |
| Approved | Type I Interferon receptor (IFNAR)Biologic (subtype unspecified) | Multiple Sclerosis | |
| Approved | Type I interferon receptorBiologic (subtype unspecified) | Multiple Sclerosis | |
Lecanemab(Leqembi) | Approved | Amyloid-beta (monoclonal antibody)Monoclonal antibody | Alzheimer's Disease |
natalizumab(Tysabri) | Approved | α4 integrinMonoclonal antibody | Inflammatory Bowel DiseaseMultiple Sclerosis Crohn's Disease |
Pegcetacoplan ophthalmic(Syfovre) | Approved | Complement C3 · Complement C3 / C3bPeptide | Age-Related Macular Degeneration |
peginterferon beta-1a(Plegridy) | Approved | Type I interferon receptor · Interferon beta receptor (type I IFN signaling)Biologic (subtype unspecified) | Multiple Sclerosis |
| Phase 3 | LRRK2Small molecule | Parkinson's Disease | |
| Phase 3 | BDCA2 (CLEC4C) · BDCA2 / CD303 (blood dendritic cell antigen 2)Monoclonal antibody | Systemic Lupus Erythematosus | |
Pegcetacoplan(Empaveli) | Phase 3 | Complement C3Peptide | Chronic Kidney Disease |
BaminerceptNo recent activity | Phase 2 | Lymphotoxin-beta receptor (LTβR)Protein / enzyme therapeutic | Rheumatoid Arthritis |
| Phase 2 | Bruton's tyrosine kinase (BTK) | Multiple Sclerosis | |
| Phase 2 | MAPT mRNA (RNAi/ASO)RNA / oligonucleotide | Alzheimer's Disease |
Upcoming events
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.
Insider transactions
Unlock insider transactions
Research includes SEC Form 4 insider transactions: filed buys, sells, awards and exercises linked to the underlying filings.
Institutional holders
Unlock institutional holders
Research includes quarterly SEC 13F institutional ownership: top holders, aggregate positions and quarter-over-quarter context.